These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2306811

  • 1. Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase.
    Nguyen PD, O'Rear EA, Johnson AE, Patterson E, Whitsett TL, Bhakta R.
    Circ Res; 1990 Mar; 66(3):875-8. PubMed ID: 2306811
    [Abstract] [Full Text] [Related]

  • 2. Encapsulation of a plasminogen activator speeds reperfusion, lessens infarct and reduces blood loss in a canine model of coronary artery thrombosis.
    Leach JK, Patterson E, O'Rear EA.
    Thromb Haemost; 2004 Jun; 91(6):1213-8. PubMed ID: 15175809
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New developments in thrombolytic therapy.
    Collen D, Gold HK.
    Adv Exp Med Biol; 1990 Jun; 281():333-54. PubMed ID: 2129372
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators.
    N Engl J Med; 1993 Nov 25; 329(22):1615-22. PubMed ID: 8232430
    [Abstract] [Full Text] [Related]

  • 7. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY, Lorch G, Cambier PA, Hansen D, Titus BG, Martin JS, Lee JJ, Every NR, Hallstrom AP, Stock-Novack D, Scherer J, Weaver WD.
    Am Heart J; 1999 Oct 25; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Effect of thrombolytic agents on infarct size and left ventricle systolic function in myocardial infarction].
    Bassand JP, Cassagnes J, Machecourt J, Anguenot T, Lusson JR, Borel E, Schiele F, Wolf JF, Vachet D.
    Arch Mal Coeur Vaiss; 1990 Feb 25; 83 Spec No 1():31-6. PubMed ID: 2108644
    [Abstract] [Full Text] [Related]

  • 10. Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.
    Monk JP, Heel RC.
    Drugs; 1987 Jul 25; 34(1):25-49. PubMed ID: 3308411
    [Abstract] [Full Text] [Related]

  • 11. Thrombolytic treatment in acute myocardial infarction.
    Verstraete M.
    Circulation; 1990 Sep 25; 82(3 Suppl):II96-109. PubMed ID: 2118432
    [Abstract] [Full Text] [Related]

  • 12. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM.
    JAMA; 1996 Mar 13; 275(10):777-82. PubMed ID: 8598594
    [Abstract] [Full Text] [Related]

  • 13. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
    Crabbe SJ, Grimm AM, Hopkins LE.
    Pharmacotherapy; 1990 Mar 13; 10(2):115-26. PubMed ID: 2140889
    [Abstract] [Full Text] [Related]

  • 14. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T, Hermens WT, Lenderink T, Molhoek GP, Grollier G, Pfisterer M, Simoons ML.
    Eur Heart J; 1996 Feb 13; 17(2):237-46. PubMed ID: 8732377
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of a new accelerated streptokinase regime in acute myocardial infarction: a double blind randomized clinical trial.
    Ghaffari S, Kazemi B, Golzari IG.
    Cardiovasc Ther; 2013 Feb 13; 31(1):53-9. PubMed ID: 21884018
    [Abstract] [Full Text] [Related]

  • 16. Coronary thrombolysis for evolving myocardial infarction.
    Spann JF, Sherry S.
    Drugs; 1984 Nov 13; 28(5):465-83. PubMed ID: 6391890
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.
    Barbagelata NA, Granger CB, Oqueli E, Suárez LD, Borruel M, Topol EJ, Califf RM.
    Am Heart J; 1997 Mar 13; 133(3):273-82. PubMed ID: 9060794
    [Abstract] [Full Text] [Related]

  • 19. Summary of U.S. clinical trials program for evaluation of anistreplase.
    Anderson JL.
    Clin Cardiol; 1990 Mar 13; Suppl 5():V33-8; discussion V67-72. PubMed ID: 2182239
    [Abstract] [Full Text] [Related]

  • 20. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis.
    Rigel DF, Olson RW, Lappe RW.
    Circ Res; 1993 May 13; 72(5):1091-102. PubMed ID: 8477521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.